Erbitux SCCHN results confirmed
On Wednesday, ImClone (IMCL) gained $5.11 (17%) to $35.27 on 19.8 million shares after announcing that an independent analysis confirmed that Erbitux cetuximab met the primary endpoint of locoregional control in the Phase III IMCL-9815 trial to treat advanced squamous cell carcinoma of the head and neck (SCCHN). In the international trial comparing Erbitux plus radiation to radiation alone in 424 patients, Erbitux also met the secondary endpoints of overall survival and progression-free survival.
In April, IMCL and partner Bristol-Myers (BMY) decided to do additional independent analysis of the primary endpoint of IMCL-9815 so that each patient scan would be reviewed twice. In the original trial design, each patient scan was to be reviewed by either a radiation oncologist or a medical oncologist. Initially, only a small sample of cases were reviewed by both. ...